MX2021001877A - Composiciones y métodos para el tratamiento de lesión pulmonar aguda. - Google Patents
Composiciones y métodos para el tratamiento de lesión pulmonar aguda.Info
- Publication number
- MX2021001877A MX2021001877A MX2021001877A MX2021001877A MX2021001877A MX 2021001877 A MX2021001877 A MX 2021001877A MX 2021001877 A MX2021001877 A MX 2021001877A MX 2021001877 A MX2021001877 A MX 2021001877A MX 2021001877 A MX2021001877 A MX 2021001877A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- lung injury
- compositions
- methods
- acute lung
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862719217P | 2018-08-17 | 2018-08-17 | |
| PCT/US2019/046698 WO2020037146A1 (en) | 2018-08-17 | 2019-08-15 | Compositions and methods for treatment of acute lung injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021001877A true MX2021001877A (es) | 2021-07-15 |
Family
ID=69524874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021001877A MX2021001877A (es) | 2018-08-17 | 2019-08-15 | Composiciones y métodos para el tratamiento de lesión pulmonar aguda. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12070483B2 (enExample) |
| EP (1) | EP3836953A4 (enExample) |
| JP (2) | JP7483684B2 (enExample) |
| KR (1) | KR20210046698A (enExample) |
| CN (1) | CN112703009B (enExample) |
| AU (1) | AU2019321654B8 (enExample) |
| BR (1) | BR112021002920A2 (enExample) |
| CA (1) | CA3109798A1 (enExample) |
| IL (1) | IL280868B1 (enExample) |
| MX (1) | MX2021001877A (enExample) |
| WO (1) | WO2020037146A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL280868B1 (en) | 2018-08-17 | 2026-05-01 | The Trustees Of The Univ Of Pennsylvania | Compositions and methods for treating acute lung injury |
| KR20260034620A (ko) * | 2023-05-05 | 2026-03-11 | 페록시테크 인코포레이티드. | 패혈성 쇼크 치료용 조성물 및 방법 |
| US20240390452A1 (en) * | 2023-05-26 | 2024-11-28 | The Trustees Of The University Of Pennsylvania | Protective Agent Against Endothelial Dysfunction |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4861756A (en) * | 1988-03-08 | 1989-08-29 | Merrell Dow Pharmaceuticals Inc. | Synthetic pulmonary surfactant |
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| ATE173159T1 (de) | 1992-03-25 | 1998-11-15 | Depomed Systems Inc | Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe |
| WO1997047285A1 (en) | 1996-06-10 | 1997-12-18 | Depomed, Inc. | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| ES2248908T7 (es) | 1997-06-06 | 2014-11-24 | Depomed, Inc. | Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles |
| NZ518739A (en) | 1999-11-02 | 2004-12-24 | Depomed Inc | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
| PT1251832E (pt) | 2000-02-04 | 2007-01-31 | Depomed Inc | Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero |
| US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
| WO2002006301A2 (en) * | 2000-06-30 | 2002-01-24 | University Of Cincinnati | Peptides with antioxidant and antimicrobial properties |
| US6451808B1 (en) | 2000-10-17 | 2002-09-17 | Depomed, Inc. | Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists |
| US20030031711A1 (en) | 2001-05-29 | 2003-02-13 | Fara John W. | Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough |
| US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
| JP2005508358A (ja) | 2001-10-25 | 2005-03-31 | デポメド・インコーポレイテッド | 胃滞留型ロサルタン投与量を用いる治療方法 |
| CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
| MXPA04010560A (es) * | 2002-04-25 | 2005-08-15 | Scripps Research Inst | Tratamiento y prevencion de condiciones pulmonares. |
| EP1764095A1 (en) | 2005-09-20 | 2007-03-21 | Revotar Biopharmaceuticals AG | Novel nitrocatechol derivatives having selectin ligand activity |
| US9012403B2 (en) * | 2010-06-18 | 2015-04-21 | Xiberscience Gmbh | Peptides as active agents to stabilize biological barriers |
| US8962570B2 (en) * | 2011-05-17 | 2015-02-24 | University of Pittsburgh—of the Commonwealth System of Higher Education | Therapeutic use of peptide inhibitors of NADPH oxidase; aerosolization as a delivery mechanism |
| US11110152B2 (en) * | 2016-04-11 | 2021-09-07 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating and preventing lung disease |
| IL280868B1 (en) | 2018-08-17 | 2026-05-01 | The Trustees Of The Univ Of Pennsylvania | Compositions and methods for treating acute lung injury |
-
2019
- 2019-08-15 IL IL280868A patent/IL280868B1/en unknown
- 2019-08-15 MX MX2021001877A patent/MX2021001877A/es unknown
- 2019-08-15 US US17/269,097 patent/US12070483B2/en active Active
- 2019-08-15 JP JP2021507917A patent/JP7483684B2/ja active Active
- 2019-08-15 KR KR1020217007331A patent/KR20210046698A/ko not_active Ceased
- 2019-08-15 WO PCT/US2019/046698 patent/WO2020037146A1/en not_active Ceased
- 2019-08-15 CN CN201980060751.3A patent/CN112703009B/zh active Active
- 2019-08-15 CA CA3109798A patent/CA3109798A1/en active Pending
- 2019-08-15 AU AU2019321654A patent/AU2019321654B8/en active Active
- 2019-08-15 EP EP19850140.5A patent/EP3836953A4/en active Pending
- 2019-08-15 BR BR112021002920-6A patent/BR112021002920A2/pt unknown
-
2024
- 2024-05-01 JP JP2024074284A patent/JP7822065B2/ja active Active
- 2024-07-16 US US18/773,968 patent/US20250082715A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019321654B1 (en) | 2025-07-17 |
| JP7822065B2 (ja) | 2026-03-02 |
| US20210315964A1 (en) | 2021-10-14 |
| EP3836953A4 (en) | 2022-06-29 |
| BR112021002920A2 (pt) | 2021-05-11 |
| JP2021534184A (ja) | 2021-12-09 |
| CN112703009B (zh) | 2024-06-11 |
| US20250082715A1 (en) | 2025-03-13 |
| EP3836953A1 (en) | 2021-06-23 |
| US12070483B2 (en) | 2024-08-27 |
| AU2019321654B8 (en) | 2025-08-07 |
| AU2019321654A1 (en) | 2021-03-18 |
| WO2020037146A1 (en) | 2020-02-20 |
| JP2024102207A (ja) | 2024-07-30 |
| KR20210046698A (ko) | 2021-04-28 |
| IL280868B1 (en) | 2026-05-01 |
| IL280868A (en) | 2021-04-29 |
| JP7483684B2 (ja) | 2024-05-15 |
| CN112703009A (zh) | 2021-04-23 |
| CA3109798A1 (en) | 2020-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125136T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
| CY1124013T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
| CO2021001912A2 (es) | Composiciones anti-cd112r y métodos | |
| CY1123381T1 (el) | Συνθεσεις που περιεχουν βακτηριακα στελεχη | |
| CY1122148T1 (el) | Συνθεσεις που περιεχουν βακτηριακα στελεχη | |
| CY1122184T1 (el) | Συνθεσεις περιλαμβανουσες βακτηριακα στελεχη | |
| CY1122344T1 (el) | Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων | |
| CY1121473T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
| CL2022000531A1 (es) | Composiciones y métodos para el tratamiento de infecciones virales. | |
| CY1120373T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
| MD3313423T2 (ro) | Compoziții care conțin tulpini bacteriene de Blautia pentru tratamentul hipersensibilității viscerale | |
| EA201891199A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
| EA201790787A1 (ru) | Снижение вязкости фармацевтических составов | |
| EP3603636A4 (en) | COMPOSITION TARGETING S1PR4 TO PREVENT OR TREAT NON-ALCOHOLIC STEATOHEPATITIS | |
| EP3833340A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT FOR PRESBYOPIA | |
| CY1124286T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
| CL2023000892A1 (es) | Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional). | |
| EP3468555C0 (en) | COMPOSITIONS FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | |
| CO2019014647A2 (es) | Composiciones inmunogénicas | |
| EP3651801B1 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | |
| UY38352A (es) | Inhibidores de integrina alfavbeta6 | |
| IL282041A (en) | Egfr inhibitors for treating keratodermas | |
| EP3709968C0 (de) | Emulsionen zur behandlung von schleimhautinfektionen | |
| MX392976B (es) | Composiciones que comprenden cepas bacterianas. |